ZBH vs DXCM
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ZBH · Zimmer Biomet Holdings$101.10 ▼ 0.36%
DXCM · DexCom$79.32 ▼ 1.08%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ZBH +9.3%
- DXCM +27.5%
Head to head
| Metric | ZBH | DXCM |
|---|---|---|
| Price | $101.10 | $79.32 |
| Change today | ▼ 0.36% | ▼ 1.08% |
| Market cap | $19.13B | $29.58B |
| Return, 3 months | +0.4% | -12.9% |
| Return, year to date | +13.3% | +19.5% |
| Return, 1 year | +10.8% | +31.7% |
| P/E (TTM) | 25.5 | 31.2 |
| P/B | 1.5 | 11.7 |
| P/E percentile vs own 5y | 46th | 6th |
| Dividend yield | 0.95% | – |
| Revenue growth (YoY, latest qtr) | +3.1% | +11.2% |
| Net profit growth (YoY) | -16.6% | -3.1% |
| Gross margin | 69.7% | 63.4% |
| Operating margin | 16.3% | 24.0% |
| Net margin | 9.0% | 19.4% |
| Return on equity | 6.0% | 37.7% |
| Analyst target vs. price | +17.2% | +25.1% |
| Analyst buy share | 31% | 93% |
| RSI (14) | 51 | 43 |
| 30-day volatility | 46.8% | 45.7% |
| Max drawdown, 1 year | -21.0% | -22.6% |
| Trend read | Leaning bullish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- DXCM is the largest of the group by market value.
- DXCM has returned the most over the past year.
- ZBH carries the lowest trailing P/E.
- DXCM is growing revenue fastest.
- DXCM keeps the most profit per dollar of sales.
- DXCM has been the calmest stock over the last 30 days.